Celltrion Anticipates Biosimilar Gains from U.S. CMS Policy Reforms
Favorable Conditions Created for Expanded Prescriptions of Zympentra and Biosimilars
Celltrion announced on April 8 that, according to the 2027 Medicare Advantage (MA) and Part C/D payment policy reforms announced by the U.S. Centers for Medicare & Medicaid Services (CMS) on April 6 (local time), a favorable environment has been created for the company’s direct sales strategy and expansion of prescriptions for its major product lines.
The latest reform includes: ▲ a 2.48% increase in the burden on insurance companies for MA plans; ▲ a higher out-of-pocket maximum for patients, rising from $2,100 in 2026 to $2,400 in 2027; and ▲ stricter management of healthcare utilization. Overall, these changes are aimed at encouraging greater preference for pharmaceuticals with lower prices.
MA is a structure in which private insurers operate Medicare, the public health insurance program for the elderly in the United States. As the financial burden on insurers increases, there is a stronger incentive to adopt lower-priced drugs, which increases the potential for expanded use of biosimilars.
The increase in the patient out-of-pocket maximum is also likely to influence prescription choices by raising cost concerns. As a result, demand for biosimilars with relatively strong price competitiveness is expected to grow.
Criteria for managing healthcare utilization are also being tightened. The system is shifting from a disease-code-centered approach to one based on medical evidence, making cost-efficiency a key factor in decisions. Additionally, if extra costs incurred by intravenous (IV) administration are considered, preference for subcutaneous (SC) formulations that can be self-administered is also expected to rise. Celltrion’s “Zympentra” falls into this category.
These policy changes are interpreted as creating an environment that supports expanded adoption of biosimilars by simultaneously seeking cost savings for insurers, patients, and government finances.
Celltrion explained that it has established local manufacturing, supply, and direct sales networks in the U.S., thereby securing price competitiveness and bargaining power with insurers and pharmacy benefit managers (PBMs). The company also pointed out that the U.S. government’s exclusion of biosimilars from pharmaceutical tariff policies is expected to be a positive factor in line with the overall cost-reduction trend.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative stated, “This policy clearly shows the direction toward expanding the use of cost-efficient pharmaceuticals,” adding, “Based on our local production and direct sales system, we will seek to expand prescriptions within the U.S. market.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.